Teva’s Copaxone Suit Is “Absolutely Unprecedented,” FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA says Teva’s argument to court about dire impact of potential glatiramer ANDAs does not match its statements to investors.
You may also be interested in...
US Ruling Confirms Copaxone Is Not A Biologic
US FDA’s interpretation of ‘protein’ is reasonable and owed deference, the court concludes in tossing Teva suit which challenged Copaxone’s exclusion from list of drugs transitioned to being regulated as biologics.
Copaxone Legal Fight May Finally Be Over As Court Finds The MS Treatment Is Not A Biologic
US FDA’s interpretation of ‘protein’ is reasonable and owed deference, the court concludes in tossing Teva suit which challenged Copaxone’s exclusion from list of drugs transitioned to being regulated as biologics.
Mylan/Natco, Sandoz/Momenta Stew As Teva Cements Copaxone Loyalty
Teva’s multiple sclerosis drug Copaxone lost patent protection about three weeks ago. But according to some analysts an immediate generic substitution is still up in the air and the company has not lost the opportunity to capitalize in the interim by switching patients to a new three-injections-a-week formulation.